Trials / Unknown
UnknownNCT04382768
Inhaled Ibuprofen to Treat COVID-19
Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Química Luar SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled Hypertonic ibuprofen | Standard of care plus lipid ibuprofen 50mg tid |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
- First posted
- 2020-05-11
- Last updated
- 2020-06-11
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT04382768. Inclusion in this directory is not an endorsement.